Breast cancer is the most common cancer in women globally, and compared to other cancers is one that appears at all ages, though rates increase with rates. While most cases occur sporadically, an approximate 5-10% of cancers are linked to inherited gene mutations, such as BRCA1 and BRCA2.
To determine optimal treatment, breast cancer types are categorized based on many factors, such as the histopathological type, the tumor grade, the stage, and its gene and protein expressions. To get a full picture the latter category is again divided into two or more classification systems: •
- The most common way to look at expression differences, is to determine the cancer’s receptor status: estrogen receptor (ER), progesterone receptor (PR) and HER2. Cells are classified based on the presence or absence of these receptors, for example, as ER-positive or ER-negative. Cells that lack these receptors entirely, or express them at very low levels, are referred to as basal-like or triple-negative.
- The identification of specific DNA mutations or gene expression patterns in cancer cells may guide treatment decisions; either by enabling targeted therapies aimed at these changes, or by indicating which non-targeted treatments are likely to be most effective based on these alterations.
Peptides in Breast Cancer Research
At JPT, we provide a variety of peptides for:
- Targeted Drug Delivery: Peptides can be syntecized to specically target and bind to over- and underexpressed receptors (e.g. ER or HER).
- Gene therapy: Adenoviridae (AdV) are the most commonly researched viral vectors for anti-cancer therapy, by modifiying a host cell’s genetic expression without the integrating into its DNA.
- Diagnostics and Imaging Tools:
- Biomarker Discovery: Arrays
- Radiosensiziztation
Peptide Tools to Study Breast Cancer
Sort by
